MIT Says It No Longer Stands Behind Student's AI Research Paper
The Massachusetts Institute of Technology said Friday it can no longer stand behind a widely circulated paper on artificial intelligence written by a doctoral student in its economics program.
The paper said that the introduction of an AI tool in a materials-science lab led to gains in new discoveries, but had more ambiguous effects on the scientists who used it.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
2 hours ago
- Time Magazine
15 of the Most Important Inventions of All Time According to AI
This article is published by a partner of TIME. Inventions are the building blocks of civilization, shaping everything from our daily routines to the entire global economy. From the first stone tools created by our ancestors to the cutting-edge technologies driving innovation today, human creativity has consistently led to breakthroughs that improve lives and change the course of history. Some inventions have dramatically altered entire industries, while others have redefined our interaction with the world around us, pushing the boundaries of what's possible. The following list highlights 15 of the most important inventions of all time, selected for their far-reaching impact and transformative influence on society. These inventions have laid the foundation for modern life, from medicine and communication to transportation and energy. With the research assistance of AI, we will explore how these breakthroughs have shaped the world and continue to do so today. Here are the 15 inventions that stand out as some of the most influential throughout history. Breakthrough Inventions 1. The Wheel (3500 BC) The wheel is one of the oldest and most important inventions, dating back to around 3500 BC. Originally used for pottery, it soon found application in transportation, revolutionizing human mobility. The ability to transport goods and people over long distances led to the growth of trade and connected far-flung cultures. The wheel also became a critical component in machinery, laying the foundation for the Industrial Revolution and modern engineering. Additional Insights: Engineering Impact: It has been used in countless machines and continues to be foundational in modern engineering. Transportation: The wheel made it possible to move goods and people quickly and efficiently, boosting trade. Symbol of Innovation: It's often seen as a symbol of human ingenuity and problem-solving. Global Adoption: Its utility spread across the world, influencing various civilizations and industries. 2. The Printing Press (1440) Johannes Gutenberg's invention of the printing press in 1440 dramatically changed the dissemination of information. By making it possible to mass-produce books, pamphlets, and newspapers, it allowed knowledge to be distributed widely and inexpensively. This invention played a crucial role in the Renaissance, Reformation, and the spread of scientific ideas. The printing press was key to the democratization of knowledge and laid the foundation for modern education and the information age. Additional Insights: Knowledge Distribution: Books became affordable, allowing information to reach a much wider audience. Cultural Shift: The press helped spread ideas that challenged religious and political norms, such as during the Reformation. Scientific Advancements: It enabled the rapid dissemination of new scientific discoveries, propelling the Scientific Revolution. Global Impact: Its influence extended across Europe and beyond, shaping societies worldwide. Enduring Legacy: Paved the way for the modern information society. 3. The Atomic Bomb (1945) Developed during World War II, the atomic bomb was a revolutionary and highly controversial invention. Its creation led to the first use of nuclear weapons in warfare, resulting in the bombings of Hiroshima and Nagasaki in 1945. While its destructive power reshaped global politics and military strategy, it also sparked the nuclear arms race and significant shifts in geopolitical relations during the Cold War. The atomic bomb's legacy continues to influence the field of international relations and nuclear disarmament. Additional Insights: World War II Impact: It helped bring the war to a close but raised ethical questions about the use of such destructive weapons. Nuclear Arms Race: Initiated the Cold War competition between the United States and the Soviet Union. Geopolitical Shifts: Nuclear weapons fundamentally altered military strategies and global diplomacy. Nuclear Energy: The underlying technology contributed to the development of nuclear energy for peaceful purposes. Moral Dilemmas: Sparked global debates about the morality and necessity of nuclear weapons in warfare. 4. Electricity (18th–19th Centuries) Electricity powers nearly all modern technology, from lighting in homes to methods of communication, transportation, and industry. Discovered and refined throughout the 18th and 19th centuries, it paved the way for countless innovations, including the telegraph, electric motors, and telecommunications. Its widespread adoption during the Industrial Revolution allowed factories to run more efficiently, transforming economies and improving quality of life. Today, electricity remains essential in almost every aspect of daily life. Additional Insights: Early Discoveries: Benjamin Franklin, Michael Faraday, and Thomas Edison made key contributions. Industrial Impact: Powered the growth of various manufacturing sectors and mass transportation. Technological Advancements: Enabled telegraphy, radio, television, and eventually the computer and internet. Global Accessibility: Powers homes and businesses worldwide, essential for modern living. Sustainability Challenges: The quest for renewable energy sources remains central to the future of electricity generation. 5. The Telephone (1876) Invented by Alexander Graham Bell in 1876, the telephone allowed for instant communication over long distances, revolutionizing how people connect. Before the telephone, communication was limited to written letters or telegrams, which could take days to deliver. The invention enabled real-time conversations and opened up new possibilities for business, government, and personal connections. Today, the telephone has evolved into the smartphone, which plays a central role in daily life. Additional Insights: First Words: Bell's first successful telephone call was 'Mr. Watson, come here, I want to see you.' Global Connectivity: Made distant communication fast and efficient, fostering a new era of interconnectedness. Business Revolution: Allowed organizations to operate more effectively and make decisions quickly. Modern Evolution: The landline phone transformed into mobile phones and smartphones. Telecommunications Industry: Gave rise to a vast global industry dedicated to communication technologies. 6. Penicillin (1928) Penicillin, discovered by Alexander Fleming in 1928, was the first antibiotic and revolutionized medicine. It allowed doctors to treat previously fatal bacterial infections, drastically reducing mortality rates and ushering in the era of modern antibiotics. This breakthrough saved millions of lives and paved the way for other lifesaving antibiotics. Today, penicillin remains a cornerstone of medical treatments, although challenges such as antibiotic resistance have emerged. Additional Insights: Life-Saving Discovery: Dramatically reduced deaths from infections once considered fatal. Medical Impact: Initiated the antibiotic era, radically changing the treatment of infectious diseases. Global Health: Its use is widespread, reaching patients worldwide. Antibiotic Resistance: Overuse has led to resistant strains of bacteria, a growing global concern. Ongoing Research: Scientists continue to develop new antibiotics to combat evolving pathogens. 7. The Airplane (1903) The invention of the airplane by the Wright brothers in 1903 forever changed human travel. For the first time, flight over long distances became possible, shrinking the world and enabling global commerce and tourism. Airplanes transformed industries like international business and leisure travel, making transit faster and more accessible. Today, air travel is one of the most essential forms of long-distance transportation. Additional Insights: First Flight: The Wright brothers' initial flight lasted just 12 seconds, ushering in the aviation age. Global Connectivity: Made cross-continental and intercontinental travel feasible in mere hours. Economic Impact: Aviation is vital for modern commerce, connecting businesses and services worldwide. Technological Advances: Fuel-efficient planes and improved safety measures continue evolving. Future Developments: Electric and autonomous flying vehicles may soon redefine air travel again. 8. The Computer (1940s) The invention of the computer has had a profound impact on almost every aspect of human life. Early computers in the 1940s were large machines used primarily for military and scientific calculations. With the advent of personal computers in the 1970s and 1980s, computing power became accessible to the masses, driving the digital revolution. Computers are now central to business, education, communication, and entertainment, and they continue to evolve through innovations in artificial intelligence, big data, and cloud computing. Additional Insights: Early Models: The first computers occupied entire rooms and performed complex calculations. Personal Computing: The rise of home and office computers democratized access to technology. Global Connectivity: Computers power the internet, enabling global communication and collaboration. Technological Growth: Laptops, smartphones, and tablets have integrated computing into daily life. AI and Beyond: Modern computers support advanced technologies like machine learning. 9. Email (1970s) Email transformed communication by enabling people to send and receive messages instantly across long distances. Developed in the early 1970s, it quickly replaced traditional mail and telegrams for many uses, offering a faster and more efficient medium. Email is indispensable in personal and professional contexts, allowing real-time communication and easy document sharing. Despite the rise of social media and instant messaging, email remains one of the most widely used communication tools today. Additional Insights: Business Efficiency: Streamlined workplace communication, reducing the need for physical memos and meetings. Global Reach: Made it possible to communicate instantly with anyone anywhere in the world. Security Considerations: Phishing attacks and spam are modern challenges in email usage. Email Evolution: Integration with calendars, task managers, and file-sharing solutions is commonplace. 10. Television (1930s) Television fundamentally altered how information and entertainment are consumed. By the 1930s, it had become a popular medium for delivering news, shows, and educational content. TV shaped global culture and opinion, serving as a powerful platform for political discourse, advertising, and mass communication. The medium continues to evolve with the rise of streaming services and on-demand viewing, offering audiences a wealth of content anytime, anywhere. Additional Insights: Broadcasting: Revolutionized mass communication by reaching large audiences at once. Cultural Impact: Influenced everything from music to politics on a global scale. Technological Innovation: Shift to digital and high-definition improved quality and accessibility. Global Connectivity: Networks and streaming platforms bring international events to viewers worldwide. Future of TV: On-demand and interactive features are redefining the viewing experience. 11. The Refrigerator (1834) The refrigerator changed how people preserved and stored food, improving public health by preventing spoilage and reducing foodborne illnesses. Before refrigeration, methods like salting and drying were common but inefficient. By enabling long-term storage, the refrigerator revolutionized the food industry, making mass production and distribution of perishable goods possible. It's now a kitchen staple worldwide. Additional Insights: Food Safety: Maintains safe temperatures to prevent bacterial growth. Energy Efficiency: Modern designs focus on reducing electricity consumption. Environmental Impact: Early models used harmful chemicals; newer units use more eco-friendly refrigerants. Global Distribution: Essential for international trade in perishable items. Smart Technology: Some modern refrigerators come with connectivity features for better inventory management. 12. The Light Bulb (1879) Invented by Thomas Edison in 1879, the practical light bulb changed how people lived by providing a reliable source of artificial light. It extended productive hours beyond daylight, boosted nighttime safety, and influenced the layout of modern cities. The light bulb also led to the establishment of electrical grids powering homes and businesses. Contemporary designs like LEDs have made lighting more energy-efficient and environmentally friendly. Additional Insights: Early Developments: Edison and other inventors like Joseph Swan made key breakthroughs. Cultural Impact: Allowed activities to continue past sunset and enhanced public safety. Energy Efficiency: LEDs and CFLs are reducing global energy usage. Worldwide Adoption: Became a universal standard in households and commercial spaces. Environmental Impact: Ongoing push for sustainable lighting to cut electricity consumption. 13. The Automobile (1885) Invented by Karl Benz in 1885, the automobile revolutionized transportation, allowing personal mobility on an unprecedented scale. People could travel long distances rapidly, reshaping urban design and fueling suburban growth. The global adoption of cars propelled trade and commerce, but also led to environmental concerns tied to fossil fuel consumption. Innovations like electric and hybrid vehicles continue to shape the industry's future. Additional Insights: Assembly Line: Henry Ford's production methods made cars affordable for the masses. Economic Growth: The auto industry is a massive global employer and economic driver. Environmental Challenges: Emissions drive the push toward electric and alternative-fuel vehicles. Suburbanization: Cars enabled the rise of suburbs and changed city infrastructures. Future Innovations: Autonomous vehicles promise another revolution in transportation. 14. The Radio (1890s) Radio transformed communication by transmitting sound over long distances through electromagnetic waves. First demonstrated in the 1890s by innovators like Guglielmo Marconi and Nikola Tesla, it became wildly popular in the early 20th century for news, music, and entertainment. Radio gave rise to shared cultural experiences and played an influential role in shaping public opinion, especially during significant historical events. Additional Insights: First Broadcast: Marconi's successful transmission in 1901 was a landmark in wireless communication. Cultural Influence: Radio dramas, music, and news broadcasts became staples of daily life. Global Reach: Served as a vital communication method for people in remote areas. Evolution of Radio: FM radio and digital broadcasting expanded the medium's range and quality. Media Convergence: Online streaming and podcasts continue to adapt radio for the digital era. 15. The Camera (Early 19th Century) The invention of the camera revolutionized how we capture memories, document events, and record history. Joseph Nicéphore Niépce took the first permanent photograph in 1826, and camera technology has evolved continuously since then—from bulky film cameras to compact digital devices. Photography has greatly impacted art, journalism, and personal expression, enabling people to preserve and share moments in real time. Additional Insights: First Photograph: Taken by Niépce in 1826, marking the birth of modern photography. Cultural Impact: Influenced visual art, media, and public perception. Technological Progress: Digital cameras and smartphone integration have made photography ubiquitous. Social Media: Photos are at the heart of social platforms, fostering global visual storytelling. Historical Documentation: Cameras have captured landmark events, shaping our collective memory. Conclusion on Key Inventions These 15 inventions have fundamentally shaped human civilization, influencing everything from how we communicate and travel to how we work and live. Each marks a leap forward in human ingenuity that addressed critical needs and created opportunities for continued progress. Their impact reverberates in modern industries, improving the quality of life for countless people around the world. As we look to the future, these foundational innovations serve as a springboard for even more groundbreaking developments. The spirit of creativity and the relentless drive to overcome global challenges will fuel progress, bringing about new inventions that will once again transform the world in ways we can only imagine. Related Articles: About the Authors: Richard D. Harroch is a Senior Advisor to CEOs, management teams, and Boards of Directors. He is an expert on M&A, venture capital, startups, and business contracts. He was the Managing Director and Global Head of M&A at VantagePoint Capital Partners, a venture capital fund in the San Francisco area. His focus is on internet, digital media, AI and technology companies. He was the founder of several Internet companies. His articles have appeared online in Forbes, Fortune, MSN, Yahoo, Fox Business and Richard is the author of several books on startups and entrepreneurship as well as the co-author of Poker for Dummies and a Wall Street Journal-bestselling book on small business. He is the co-author of a 1,500-page book published by Bloomberg on mergers and acquisitions of privately held companies. He was also a corporate and M&A partner at the international law firm of Orrick, Herrington & Sutcliffe. He has been involved in over 200 M&A transactions and 250 startup financings. He can be reached through LinkedIn. Dominique Harroch is the Chief of Staff at She has acted as a Chief of Staff or Operations Leader for multiple companies where she leveraged her extensive experience in operations management, strategic planning, and team leadership to drive organizational success. With a background that spans over two decades in operations leadership, event planning at her own start-up and marketing at various financial and retail companies, Dominique is known for her ability to optimize processes, manage complex projects and lead high-performing teams. She holds a BA in English and Psychology from U.C. Berkeley and an MBA from the University of San Francisco. She can be reached via LinkedIn.
Yahoo
2 hours ago
- Yahoo
Rocket Lab Stock Is Soaring Again: Should You Buy It Under $30?
Rocket Lab is gaining a reputation for reliability in the rocket launch and space systems market. The company is building on its capabilities and improving its relationships as a defense contractor. While this young sector shows a lot of great promise, the stock looks overvalued today. 10 stocks we like better than Rocket Lab › Space is the final frontier, and it is now turning into a burgeoning economy. Researchers estimate that the space economy is worth over $500 billion with heavy spending from governments around the world along with private-company partners, and that figure is expected to grow to around $1.8 trillion a year by 2035. This is a huge opportunity for start-ups, perhaps rivaled only by artificial intelligence (AI) over the next decade when it comes to both growth rates and size. One company that dominates (and actually built) the entire space market is SpaceX. It's privately held, but luckily, investors have other space economy stocks that are turning into promising businesses. Enter Rocket Lab (NASDAQ: RKLB), the space flight company increasingly competing with SpaceX and developing promising capabilities to grow its presence in this large market. The stock has begun to soar again and is trading at around $26 as of this writing. Should you buy while shares are still under $30? Rocket Lab began its journey in the space economy with its small Electron rocket. It has now begun to expand and vertically integrate various space economy segments. It just acquired a company called Geost for $275 million. Geost develops optical and infrared capabilities for satellites with a focus on selling to the U.S. government's national security satellites. Rocket Lab is used by the government to launch its payloads into space. Now, it will be helping to build and operate these payloads for customers. It keeps vertically integrating its launch and space systems, which gives it a competitive advantage over other companies that only offer one or the other (SpaceX is the only other vertically integrated player). Rocket Lab offers solar energy, radio systems, and software for companies sending missions operating in space. This is why its backlog was over $1 billion as of the end of last quarter. Electron launch missions will continue throughout 2025, hopefully building on the company's strong safety and reliability record. The next step for the company will be testing and launching its larger Neutron rocket for customers. Testing is underway for this rocket right now with a planned mission for a confidential customer sometime in 2026. Larger rockets mean larger payloads, which means more revenue per launch. It also will give the company more of an opportunity to sell its space systems on these launches. The Neutron is the key for Rocket Lab to take the next step in its capabilities as a space flight company and to grow its backlog and revenue. Defense contracts have been a huge part of Rocket Lab's business. It currently helps with Air Force missions and a hypersonic testing program called HASTE. It was recently added to the National Security Space Launch (NSSL) program for its Neutron rocket, another reason why this new rocket is so important for the company's future. A growing relationship with the U.S. government could not have come at a better time for Rocket Lab. The government is set on spending a ton of money on space solutions as the next frontier in national defense. For example, the proposed Golden Dome missile defense project for the U.S. would cost an estimated $175 billion over three years to build. The company would be a prime candidate to win subcontracts for this ambitious project. As the Neutron comes on line and Rocket Lab builds up its capabilities and reputation in the space economy, we should see its backlog climb higher. This is a key indicator for investors to watch. The current backlog will have around half of its revenue recognized over the next 12 months, and half in later periods. In order to grow revenue over the long term, the company will need to grow its backlog and win more contracts from government and commercial customers. There is a lot of potential with Rocket Lab's business, but it might all be priced into the stock (and more) right now. It has a market cap of $12.3 billion. Revenue was only $466 million over the last 12 months. The company has never generated a profit and continues to lose money. If the company is successful with its ambitions to build a vertically integrated space company, it will eventually generate billions of dollars in revenue -- perhaps tens of billions 15 to 20 years from now. However, that is a long way off, and the stock looks fully priced versus what the company can accomplish in the next few years. For this reason, the stock looks like one to avoid even with the price under $30. The business may be promising, but the market is getting ahead of itself with Rocket Lab at the moment. This is a high-risk stock to keep out of your portfolio right now. Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab USA. The Motley Fool has a disclosure policy. Rocket Lab Stock Is Soaring Again: Should You Buy It Under $30? was originally published by The Motley Fool
Yahoo
2 hours ago
- Yahoo
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
While Epogen and Neupogen addresses anemia and neutropenia, no therapy has existed for the treatment of lymphopenia until ANKTIVA® –The Cancer BioShield. Landmark overall survival benefit (P-value 0.005, HR: 0.46 [0.26, 0.80]) observed in 3rd-6th line metastatic pancreatic cancer, correlated with reversal of lymphopenia. Patients with lower tumor burden and improved lymphocyte counts (ALC ≥1,000) had a median overall survival of 10.1 months, supporting earlier intervention in the disease course. CULVER CITY, Calif., June 03, 2025--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of lymphopenia, a well-established root cause of early mortality in patients with cancer across all tumor types, correlates with significant improved survival. While anemia and neutropenia have long been addressed by agents like Epogen and Neupogen, no therapy has ever existed for lymphopenia—until now. ANKTIVA (nogapendekin alfa inbakicept-pmln), an IL-15 superagonist approved in April 2024 for BCG-unresponsive non-muscle- invasive bladder cancer carcinoma in situ with or without papillary disease, represents the first lymphocyte-stimulating agent (LSA) capable of expanding lymphocytes critical for immunogenic cell death, such as natural killer (NK) and T cells. These findings emphasize the need for a therapy to overcome treatment induced lymphopenia with higher mortality as presented at ASCO 2025 by several institutions (Abstract #8054, Satoskar et al. and Abstract #2663, Saleh et al.) In a single-arm QUILT-88 clinical trial of 86 participants with third-to-sixth-line metastatic pancreatic cancer with very high tumor burden (CA19-9 levels exceeding 34,000 IU/ml), for which no therapy currently exists, patients received ANKTIVA subcutaneously in combination with off-the-shelf, ex-vivo infusion of CAR-NK cells (PD-L1 t-haNK) and low dose immuno-modulating chemotherapy. This first reported study of treating lymphopenia demonstrated significant differences in median overall survival in subjects whose lymphopenia was reversed (Absolute Lymphocyte Count: ALC ≥ 1,000). In 67 out of 86 subjects, reversal of lymphopenia was achieved and median overall survival was significantly prolonged compared to those who remained in severe lymphopenia with P-value 0.005, HR: 0.46 (0.26, 0.80) in Figure 1. In subjects with lymphopenia rescue and a lower tumor burden (less than the median CA19-9 of 34,000 IU/mL), the median overall survival in these very advanced metastatic pancreatic cancer patients exceeded 10 months (Figure 2). These findings of improved survival in pancreatic cancer patients with lower tumor burden point to the potential of further prolonged overall survival in pancreatic cancer patients if treated in the first line or neoadjuvant stages of disease. Highlighting the importance of lymphopenia reversal, Oncologist published a peer-reviewed paper titled "Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate," demonstrating that in a patient with 2nd line metastatic pancreatic cancer treated with the full Cancer BioShield platform—including ANKTIVA, CAR-NK cells (PD-L1 t-haNK), and antigen-targeting adenoviruses—remained in remission for over six years and maintains a high quality of life at the date of this release. The expanded access authorization announced yesterday enables patients across all solid tumor types who have exhausted first-line therapy including chemotherapy, radiation, or immunotherapy to receive Anktiva as a lymphocyte stimulating agent to protect the immune system from the lymphogenic adverse effects of current standards of care. The ASCO Annual Meeting 2025 materials from ImmunityBio can be found below: Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3rd line or greater metastatic pancreatic Text: Poster PDF: About the Cancer BioShield™ Platform The Cancer BioShield platform is a first-in-class immunotherapy strategy designed to restore immune competence by reversing lymphopenia—the loss of functional immune cells caused by cancer itself and by conventional treatments such as chemotherapy, radiation and immunotherapy. At its core is ANKTIVA® (nogapendekin alfa inbakicept-pmln), an IL-15 agonist approved for BCG-unresponsive non-muscle-invasive bladder cancer CIS with or without papillary disease, activates and proliferates natural killer (NK) cells and CD4+ and CD8+ T cells, restoring lymphocyte levels critical for immunosurveillance, immunogenic cell death, and long-term tumor control. The platform employs a multi-modal approach: In-vivo stimulation: Subcutaneous administration of ANKTIVA expands NK and T cells, boosting anti-tumor immunity. Ex-vivo targeted cytotoxicity: Off-the-shelf PD-L1 t-haNK CAR-NK cells are engineered to target and eliminate PD-L1–expressing tumor cells and immunosuppressive neutrophils (myeloid-derived suppressor cells), enhancing anti-tumor specificity and reducing immune evasion. Memory Cytokine-Enriched Natural Killer (M-ceNK) cell therapy: M-ceNK cells are developed via cytokine activation and expansion of autologous and allogeneic NK cells collected through apheresis, potentially providing long-term immune memory and sustained cytotoxic capacity. Together, these components offer a comprehensive, novel, immune-restoring therapeutic platform aimed at not only expanding effector immune cells but also overcoming tumor-mediated immune suppression to support long-term disease control. The platform's effectiveness can be tracked through universally utilized, simple complete blood count (CBC): increases in absolute lymphocyte count (ALC) reflect ANKTIVA's lymphocyte-stimulating activity, while reductions in the neutrophil-to-lymphocyte ratio (NLR) demonstrate PD-L1 t-haNK's immunosuppressive neutrophil targeting. Low ALC and high NLR levels are laboratory measurements that have been extensively reported as predictive biomarkers of poor prognosis with early mortality across all tumor types5,6. The data presented by ImmunityBio for the first time demonstrates that improving ALC and NLR correlates with significant enhanced overall survival and clinical benefit. About Lymphopenia and Absolute Lymphocyte Count (ALC) Lymphopenia—the loss of key immune cells such as NK, CD4+, and CD8+ T cells—is a common side effect of chemotherapy1, radiation2,3, and some immunotherapies4. Unlike anemia and neutropenia, which have FDA-approved treatments like EPO and Neupogen, no therapy previously existed to treat this immune cell depletion. Lymphopenia weakens the immune system, increases infection risk, and is linked to early death across many cancer types5. Low Absolute Lymphocyte Count (ALC) is a recognized poor prognostic marker. ANKTIVA® is the first approved therapy to restore lymphocyte levels by activating and expanding NK and T cells—without increasing immunosuppressive T regulatory cells7. More information on lymphopenia could be found on Twitter/X @DrPatSoonShiong articles here: References: Ray-Coquard I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009 Jul 1;69(13):5383-91. doi: 10.1158/ Epub 2009 Jun 23. PMID: 19549917; PMCID: PMC2775079. Chen D, et al. Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials. Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):196-203. doi: 10.1016/ Epub 2020 Feb 7. Pike LRG, et al. The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):142-151. doi: 10.1016/ Epub 2018 Sep 15. PMID: 30227198. Lee, Y.J., et al. Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer. Sci Rep 12, 626 (2022). Ménétrier-Caux C., et al. Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines? J Immunother Cancer. 2019 Mar 28;7(1):85. doi: 10.1186/s40425-019-0549-5. PMID: 30922400; PMCID: PMC6437964. Templeton AJ, et al. Prognostic role of neutrophil-to-lymphocyte (NLR) ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014 May 29;106(6):dju124. doi: 10.1093/jnci/dju124. PMID: 24875653. FDA ANKTIVA Label, April 2024 - About ImmunityBio ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding clinical trial data and potential results and implications to be drawn therefrom, the expectation that the EAP described herein will enable access to ANKTIVA for patients across all solid tumor types who have exhausted first-line therapy including chemo, radiation or immunotherapy, the RMAT designation as previously reported and potential results therefrom and regulatory submissions in connection therewith, the belief that ALC levels and NLR levels obtained from a CBC are predictors of clinical benefit and outcomes relating to overall survival, the belief that improving ALC levels and NLR levels correlates with enhanced overall survival and clinical benefit, the belief that reversal of lymphopenia correlates with improved survival, clinical trial and expanded access program enrollment, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's Cancer BioShield platform, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents for the prevention or reversal of lymphopenia, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that has the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "is," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, (ii) whether the RMAT designation will lead to an accelerated review or approval, of which there can be no assurance, (iii) risks and uncertainties regarding commercial launch execution, success and timing, (iv) risks and uncertainties regarding participation and enrollment and potential results from the expanded access clinical investigation program described herein, (v) whether clinical trials will result in registrational pathways and the risks, (vi) whether clinical trial data will be accepted by regulatory agencies, (vii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (viii) potential delays in product availability and regulatory approvals, (ix) ImmunityBio's ability to retain and hire key personnel, (x) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (xi) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xii) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xiii) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xiv) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on May 12, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. View source version on Contacts ImmunityBio Contacts: Investors Hemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 Media Sarah Singleton ImmunityBio, Inc. +1 Sign in to access your portfolio
